Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML

This article was originally published in Scrip

Executive Summary

In its final guidance, the health technology appraisal institute for England and Wales, NICE, has stuck to an earlier recommendation that saw Bristol-Myers Squibb's Sprycel (dasatinib) lose out to Novartis' Tasigna (nilotinib) as an NHS funded treatment option for chronic and accelerated phases of chronic myeloid leukaemia (CML) that is resistant or intolerant to standard-dose imatinib (Novartis' Glivec).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts